Overview

We believe ChemoCentryx has established the broadest pipeline of novel drugs targeting chemokine receptors in the pharmaceutical industry. We are internally discovering and developing several clinical- or preclinical-stage small molecule compounds, each targeting a distinct chemokine or chemoattractant receptor. Our compounds are designed to be highly potent, selective to minimize the risk of off-target effects and orally-available for improved patient compliance. As small molecules, they are also easier and less costly to manufacture than protein therapeutics, or biologics.

Our most advanced drug candidate, Traficet-EN™ (CCX282 or GSK'786 or recent USAN accepted name, vercirnon) which targets the CCR9 chemokine receptor, is currently in four pivotal Phase III clinical trials being conducted by our partner GSK for the treatment of patients with moderate-to-severe Crohn's disease. CCX140, our lead independent drug candidate, which targets the CCR2 chemokine receptor, successfully completed a trial for Type 2 diabetes and is currently in two Phase II clinical trials in patients with diabetic nephropathy, a form of kidney disease. CCX354, a CCR1 inhibitor, successfully completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis, or RA. This successful Phase II proof-of-concept clinical trial triggered GSK's option rights under our collaboration agreement. GSK exercised its option to further develop and commercialize CCX354 in November of 2011 and has an exclusive right to initiate a Phase IIb clinical trial for CCX354 in RA. CCX168, a C5aR inhibitor, completed Phase I clinical evaluation and is currently in a Phase II proof-of-concept clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA-associated vasculitis, or AAV, and is subject to GSK's option. CCX872, our independent next generation CCR2 drug candidate for the treatment of metabolic diseases, is expected to enter a Phase I clinical trial in the second half of 2012. CCX507, our independent drug candidate for the treatment of inflammatory bowel disease, or IBD resulted from our de novo CCR9 program. CCX662, our independent drug candidate for the treatment of glioblastoma multiforme, or GBM, is expected to enter a Phase I clinical trial in the first half of 2013.

In addition, we have several programs currently in development candidate selection which target one of several novel chemokine or chemoattractant receptors.

^ Return to Top